AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30409765 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook advertising for recruitment
Number of subjects: 1145
Study 26968881 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (400 mg) plus penicillin (1,000,000 IU) for 10 days and 7 days respectively
Number of subjects: 200
Study 26968881 — intervention group
Group type: COMPARATOR
Intervention: Penicillin (1,000,000 IU) alone
Number of subjects: 200
Study 26968881 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole plus penicillin
Number of subjects: 200
Study 26968881 — intervention group
Group type: COMPARATOR
Intervention: Penicillin alone
Number of subjects: 200
Study 25362813 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatynib-Biofarm 100 mg film-coated tablet (test)
Number of subjects: 85
Study 25362813 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatynib-Biofarm 400 mg film-coated tablet (test)
Number of subjects: 85
Study 22445084 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed prenotification letter
Number of subjects: 1000
Study 22445084 — intervention group
Group type: EXPERIMENTAL
Intervention: Faxed prenotification letter
Number of subjects: 1000
Study 22445084 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires sealed with a label marked attention to doctor
Number of subjects: 1000
Study 22445084 — intervention group
Group type: COMPARATOR
Intervention: Questionnaires sealed with a control label
Number of subjects: 1000
Study 22445084 — intervention group
Group type: EXPERIMENTAL
Intervention: More personalized approach at final reminder
Number of subjects: 1000
Study 22445084 — intervention group
Group type: COMPARATOR
Intervention: Less personalized approach at final reminder
Number of subjects: 1000
Study 20200284 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Care Model (CCM) intervention
Number of subjects: 119
Study 20200284 — intervention group
Group type: COMPARATOR
Intervention: Provider education only (PROV)
Number of subjects: 119
Study 20200284 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 119
Study 18028245 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupin challenge in peanut-allergic children (N=9)
Number of subjects: 93
Study 18028245 — intervention group
Group type: COMPARATOR
Intervention: Lupin challenge in atopic controls (N=46)
Number of subjects: 93
Study 18028245 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitization to lupin in peanut-allergic children
Number of subjects: 93
Study 18028245 — intervention group
Group type: COMPARATOR
Intervention: Sensitization to lupin in atopic controls
Number of subjects: 93
Study 27946605 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus amifostine (RT+AF)
Number of subjects: 49
Study 27946605 — intervention group
Group type: COMPARATOR
Intervention: RT only
Number of subjects: 49
Study 27946605 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+AF
Number of subjects: 49
Study 12021830 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g oral glucose tablets
Number of subjects: 41
Study 12021830 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo tablets
Number of subjects: 41
Study 10423646 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 tablets of potassium-magnesium citrate per day
Number of subjects: 61
Study 10423646 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 tablets of potassium-magnesium citrate per day
Number of subjects: 61
Study 10423646 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 tablets of potassium-magnesium citrate per day
Number of subjects: 61
Study 9001445 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin tolerance test (ITT)
Number of subjects: 10
Study 9001445 — intervention group
Group type: COMPARATOR
Intervention: Cold pressor test (CPT)
Number of subjects: 10
Study 9001445 — intervention group
Group type: COMPARATOR
Intervention: Handgrip test (HT)
Number of subjects: 10
Study 2391183 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 degrees C thermoplasticized gutta-percha with sealer
Number of subjects: 0
Study 2391183 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 degrees C thermoplasticized gutta-percha without sealer
Number of subjects: 0
Study 2391183 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 0
Study 2391183 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 0
Study 6271386 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide alone
Number of subjects: 57
Study 6271386 — intervention group
Group type: COMPARATOR
Intervention: Hexa-CAF regimen (hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil)
Number of subjects: 57
Study 6271386 — intervention group
Group type: COMPARATOR
Intervention: Hexa-CAF regimen
Number of subjects: 57
Study 30949233 — intervention group
Group type: EXPERIMENTAL
Intervention: RG method integrated in Flexible Assertive Community Treatment (FACT)
Number of subjects: 180
Study 30949233 — intervention group
Group type: COMPARATOR
Intervention: Standard FACT
Number of subjects: 180
Study 26259551 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual (VIS)
Number of subjects: 90
Study 26259551 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal (VER)
Number of subjects: 90
Study 26259551 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 90
Study 25398581 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg
Number of subjects: 150
Study 25398581 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine 5 mg
Number of subjects: 150
Study 24004959 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocopheryl acetate 20% spray
Number of subjects: 45
Study 24004959 — intervention group
Group type: COMPARATOR
Intervention: Permethrin 1% creme rinse
Number of subjects: 45
Study 21410418 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPE (Helping Other Partners Excel) intervention package
Number of subjects: 62
Study 21410418 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 62
Study 19597921 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 169
Study 19597921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 16733299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg
Number of subjects: 137
Study 16733299 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 137
Study 14646190 — intervention group
Group type: EXPERIMENTAL
Intervention: TACC-supplemented tea (1.1 mg thiamin, 1240 mg arginine, 52 mg caffeine, 540 mg citric acid); n=16
Number of subjects: 31
Study 14646190 — intervention group
Group type: COMPARATOR
Intervention: Control tea; n=15
Number of subjects: 31
Study 14646190 — intervention group
Group type: EXPERIMENTAL
Intervention: TACC-supplemented tea
Number of subjects: 31
Study 11041441 — intervention group
Group type: EXPERIMENTAL
Intervention: Stuartnatal Plus
Number of subjects: 30
Study 11041441 — intervention group
Group type: EXPERIMENTAL
Intervention: Materna
Number of subjects: 30
Study 9377121 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antiretroviral therapy
Number of subjects: 100
Study 9377121 — intervention group
Group type: COMPARATOR
Intervention: Deferred antiretroviral therapy
Number of subjects: 100
Study 8096549 — intervention group
Group type: EXPERIMENTAL
Intervention: Denopamine 40 mg/day
Number of subjects: 10
Study 8096549 — intervention group
Group type: EXPERIMENTAL
Intervention: Denopamine
Number of subjects: 10
Study 3517554 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (80 mg by mouth)
Number of subjects: 9
Study 3517554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29486807 — intervention group
Group type: EXPERIMENTAL
Intervention: MBCT + TAU
Number of subjects: 120
Study 29486807 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 120
Study 29532075 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 g/kg/d of protein plus testosterone
Number of subjects: 92
Study 29532075 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 g/kg/d of protein plus placebo
Number of subjects: 92
Study 29532075 — intervention group
Group type: COMPARATOR
Intervention: 0.8 g/kg/d of protein plus testosterone
Number of subjects: 92
Study 29532075 — intervention group
Group type: COMPARATOR
Intervention: 0.8 g/kg/d of protein plus placebo
Number of subjects: 92
Study 27216371 — intervention group
Group type: EXPERIMENTAL
Intervention: Offline communication with unfamiliar conversation partners
Number of subjects: 76
Study 27216371 — intervention group
Group type: EXPERIMENTAL
Intervention: Online communication with unfamiliar conversation partners
Number of subjects: 76
Study 27216371 — intervention group
Group type: COMPARATOR
Intervention: Offline communication with familiar conversation partners
Number of subjects: 76
Study 27216371 — intervention group
Group type: COMPARATOR
Intervention: Online communication with familiar conversation partners
Number of subjects: 76
Study 24704645 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymph drainage
Number of subjects: 45
Study 24704645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 45
Study 24704645 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 21855173 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 (estradiol patch)
Number of subjects: 39
Study 21855173 — intervention group
Group type: EXPERIMENTAL
Intervention: E2+CORT (estradiol patch/hydrocortisone)
Number of subjects: 39
Study 21855173 — intervention group
Group type: EXPERIMENTAL
Intervention: CORT (hydrocortisone)
Number of subjects: 39
Study 21855173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 20973322 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0125% capsaicin gel applied three times daily for 4 weeks
Number of subjects: 100
Study 20973322 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel applied three times daily for 4 weeks
Number of subjects: 100
Study 18419724 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg of 10 mg/ml isobaric 2-chloroprocaine
Number of subjects: 64
Study 18419724 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of 10 mg/ml isobaric 2-chloroprocaine
Number of subjects: 64
Study 18419724 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of 10 mg/ml isobaric 2-chloroprocaine
Number of subjects: 64
Study 16119354 — intervention group
Group type: EXPERIMENTAL
Intervention: Jittered electric stimulation pattern
Number of subjects: 3
Study 16119354 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic electric stimulation pattern
Number of subjects: 3
Study 16119354 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-model-generated pulses
Number of subjects: 3
Study 16119354 — intervention group
Group type: COMPARATOR
Intervention: Fixed-rate control
Number of subjects: 3
Study 16119354 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-electrode stimulation
Number of subjects: 3
Study 12105306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (MTX+)
Number of subjects: 0
Study 12105306 — intervention group
Group type: COMPARATOR
Intervention: No intrathecal methotrexate (MTX-)
Number of subjects: 0
Study 11794431 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg once/day for 7 days
Number of subjects: 27
Study 11794431 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg once/day for 7 days
Number of subjects: 27
Study 11794431 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 5.0 mg once/day for 7 days
Number of subjects: 27
Study 9724142 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 534
Study 9724142 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists
Number of subjects: 534
Study 9724142 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 534
Study 9724142 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 534
Study 9724142 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori positive
Number of subjects: 534
Study 9724142 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender and hypergastrinemia
Number of subjects: 534
Study 9724142 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrophic gastritis
Number of subjects: 534
Study 9724142 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term omeprazole treatment
Number of subjects: 534
Study 8040761 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at a dosage of 0.5 U/kg per week (group 1: 4 boys, 3 girls)
Number of subjects: 15
Study 8040761 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at a dosage of 1.0 U/kg per week (group 2: 6 boys, 2 girls)
Number of subjects: 15
Study 8040761 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (0.5 U/kg and 1.0 U/kg)
Number of subjects: 15
Study 2647038 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard return to full milk feeds
Number of subjects: 200
Study 2647038 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate full strength feeds with HN25 formula
Number of subjects: 200
Study 2647038 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate full strength feeds with SMA Gold Cap formula
Number of subjects: 200
Study 2647038 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate full strength feeds with Formula S
Number of subjects: 200
Study 2647038 — intervention group
Group type: COMPARATOR
Intervention: Graded return to full feeding
Number of subjects: 200
Study 2647038 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 200
Study 29847836 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 22
Study 29847836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 28397527 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional food and cash incentives
Number of subjects: 0
Study 28397527 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26224500 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback and referral to the occupational physician (N = 207)
Number of subjects: 413
Study 26224500 — intervention group
Group type: COMPARATOR
Intervention: Screening without feedback and unrestricted access to usual care (N = 206)
Number of subjects: 413
Study 23147552 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable robotic brace (Myomo) during repetitive task‐specific practice
Number of subjects: 16
Study 23147552 — intervention group
Group type: COMPARATOR
Intervention: Manual repetitive task‐specific practice
Number of subjects: 16
Study 20837371 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus ezetimibe 10 mg
Number of subjects: 2
Study 20837371 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin up-titration (40 mg to 80 mg or 20 mg to 40 mg)
Number of subjects: 2
Study 19085729 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative CT scan for measuring posterior condylar angle in group b.
Number of subjects: 57
Study 19085729 — intervention group
Group type: COMPARATOR
Intervention: Surgeon's own method with a posterior condylar angle of three degrees of external rotation in group a.
Number of subjects: 57
Study 19085729 — intervention group
Group type: COMPARATOR
Intervention: Comparison of femoral malrotation degrees between groups.
Number of subjects: 57
Study 16181608 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored behavioral medicine treatment
Number of subjects: 82
Study 16181608 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise therapy
Number of subjects: 82
Study 12848301 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDA diabetes simulator
Number of subjects: 24
Study 12848301 — intervention group
Group type: COMPARATOR
Intervention: Conventional lessons with slides and transparencies (Control Group B)
Number of subjects: 24
Study 11468787 — intervention group
Group type: EXPERIMENTAL
Intervention: No previous treatment to eradicate the infection
Number of subjects: 117
Study 11468787 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous eradication therapies
Number of subjects: 117
Study 11468787 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 117
Study 9196518 — intervention group
Group type: EXPERIMENTAL
Intervention: BAYx 1005 (500 mg twice daily)
Number of subjects: 8
Study 9196518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1436339 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO administered intravenously
Number of subjects: 20
Study 1436339 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO administered subcutaneously
Number of subjects: 20
Study 1436339 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (both intravenous and subcutaneous)
Number of subjects: 20
Study 1436339 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO
Number of subjects: 20
Study 31107119 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive mental health and psychosocial support services at Saftawi Health Center
Number of subjects: 408
Study 31107119 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard care at Nasser Health Center
Number of subjects: 408
Study 28268084 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure duration <1 year
Number of subjects: 0
Study 28268084 — intervention group
Group type: COMPARATOR
Intervention: Heart failure duration >5 years
Number of subjects: 0
Study 28268084 — intervention group
Group type: EXPERIMENTAL
Intervention: Age influence on BNP concentration
Number of subjects: 0
Study 26272324 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship program (ASP) utilizing prospective chart audit and feedback
Number of subjects: 339
Study 26272324 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 339
Study 26272324 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship program (ASP)
Number of subjects: 339
Study 23945376 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-combination therapy (ACT)
Number of subjects: 0
Study 23945376 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual parasitemia
Number of subjects: 0
Study 21346060 — intervention group
Group type: EXPERIMENTAL
Intervention: GIN therapy (n = 49)
Number of subjects: 99
Study 21346060 — intervention group
Group type: COMPARATOR
Intervention: Standard metabolic care (control, n = 50)
Number of subjects: 99
Study 19656386 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care support programme in primary care
Number of subjects: 194
Study 19656386 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 194
Study 16407807 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol plus ketorolac
Number of subjects: 60
Study 16407807 — intervention group
Group type: COMPARATOR
Intervention: Tramadol alone
Number of subjects: 60
Study 14757609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (7-session program designed to reduce television viewing)
Number of subjects: 16
Study 14757609 — intervention group
Group type: COMPARATOR
Intervention: Control group (safety and injury prevention program)
Number of subjects: 16
Study 14757609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 16
Study 14757609 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 14757609 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted difference between groups
Number of subjects: 16
Study 14757609 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted difference in percentage of children watching more than 2 h/d
Number of subjects: 16
Study 12666948 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral-B 3D Plaque Remover (three-dimensional oscillating/rotating/pulsating action)
Number of subjects: 33
Study 12666948 — intervention group
Group type: COMPARATOR
Intervention: Sonicare Plus (high-frequency vibrating action)
Number of subjects: 33
Study 9144030 — intervention group
Group type: COMPARATOR
Intervention: D-dimer plasma levels during period A (7-20 weeks)
Number of subjects: 63
Study 9144030 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer plasma levels during periods B and C (21-30 weeks and > 30 weeks)
Number of subjects: 63
Study 9144030 — intervention group
Group type: COMPARATOR
Intervention: Fibrinogen levels during period A (7-20 weeks)
Number of subjects: 63
Study 9144030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen levels during periods B and C (21-30 weeks and > 30 weeks)
Number of subjects: 63
Study 8188397 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 grams per day)
Number of subjects: 23
Study 8188397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 3309021 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological counseling
Number of subjects: 148
Study 3309021 — intervention group
Group type: COMPARATOR
Intervention: Placebo cimetidine
Number of subjects: 148
Study 3309021 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance cimetidine (400 mg at bedtime)
Number of subjects: 148
Study 29493475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleansing skin of one forearm with no-rinse 2% CHG-impregnated polyester cloth (method A)
Number of subjects: 63
Study 29493475 — intervention group
Group type: COMPARATOR
Intervention: 4% CHG liquid cleansing with rinsing on the contralateral arm, applied with non-antiseptic-impregnated cellulose/polyester cloth (method B)
Number of subjects: 63
Study 29493475 — intervention group
Group type: COMPARATOR
Intervention: 4% CHG liquid cleansing with rinsing on the contralateral arm, applied with cotton washcloth dampened with sterile water (method C)
Number of subjects: 63
Study 26585596 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL(®)XT implantable cardiac monitors (ICMs)
Number of subjects: 50
Study 26585596 — intervention group
Group type: COMPARATOR
Intervention: Permanent pacemakers (PPMs) programmed to monitoring only (ODO)
Number of subjects: 50
Study 26585596 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative predictive value for the absence of all AF
Number of subjects: 50
Study 24491073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 104
Study 24491073 — intervention group
Group type: COMPARATOR
Intervention: Medications
Number of subjects: 104